Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

Aminophylline for COPD Exacerbations: Dosage, Monitoring, Side Effects, Schemes and Mind Maps of History

Guidelines on the use of intravenous aminophylline for acute exacerbations of chronic obstructive pulmonary disease (copd), including dosing information, monitoring requirements, and potential side effects. It also discusses the importance of considering non-invasive ventilation and consulting a specialist before administration. The document also includes information on drug interactions and therapeutic drug monitoring.

What you will learn

  • How should intravenous aminophylline be administered and monitored in patients with COPD exacerbations?
  • What are the potential side effects of intravenous aminophylline and when should it be avoided?
  • What is the indication for using intravenous aminophylline in COPD exacerbations?

Typology: Schemes and Mind Maps

2021/2022

Uploaded on 09/12/2022

scream
scream 🇬🇧

4.5

(11)

276 documents

1 / 2

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
Intravenous Aminophylline (Adults)
Theophylline is a bronchial smooth muscle relaxant and bronchodilator. Intravenous (IV) theophylline is only
available as aminophylline, which is a pro-drug of theophylline.
Indication Intravenous Aminophylline may be used for ACUTE exacerbation of Chronic Obstructive Lung
Disease (COPD) - to be used as an adjunct to the management of exacerbations of COPD if there
is an inadequate response to nebulised bronchodilators.
Before using intravenous aminophylline for an exacerbation of COPD please consider
whether patient may be a suitable for Non Invasive Ventilation. (For example patients with
hypercapnic respiratory failure and a pH <7.35)
Please discuss use of intravenous aminophylline with a SpR or Consultant as potential side
effects may outweigh benefits and evidence of benefit in COPD is weak. Significant side effects
include arrhythmias and we would recommend avoiding its use in patients with any significant
arrhythmia such as Atrial Fibrillation.
The loading dose is given only if life threatening features are present and if the patient is
NOT already taking oral theophyllines.
IV Aminophylline should be the first line IV therapy in patients with COPD, whereas IV
aminophylline or IV salbutamol can be used for patients with asthma if they are not responding to
standard treatment.
We would recommend all patients with acute asthma who are ill enough to need aminophylline IV
are discussed with a SpR or consultant
Check the
drug
history
If the patient usually takes maintenance aminophylline or theophylline therapy, check the
theophylline serum level on admission and omit the loading dose.
For obese
patients
use IBW
for dosing
IBW = Ideal body weight
IBW (kg) for men = [(height (cm) – 154) x 0.9 ] + 50
IBW (kg) for women = [(height (cm) – 154) x 0.9 ] + 45.5
Loading
dose 5mg / kg aminophylline IV (max 500mg)- Write “LOADING DOSE” on the prescription
Add dose to 100mL of a compatible infusion fluid
Administer using a rate controlled infusion pump over 20 minutes
Monitoring
during the
bolus dose
If a patient experiences acute adverse effects i.e. palpitations, tachycardia, hypotension,
whilst the loading dose is being infused, the infusion may be stopped for 5-10 minutes or
administered at a slower rate. Ideally the patient should be cardiac monitored during the
loading dose for these reasons
Maintenance
dose 500 micrograms / kg / hour ( Elderly: 300 micrograms / kg / hour)
Add 500mg to 500mL or 250mg to 250mL of a compatible infusion fluid (1mg/mL).
Administer using a rate controlled infusion pump.
Prescribe as mg / hour NOT mL / hour
Maximum
concentration 25mg in 1ml Maximum rate of
administration 25mg per minute
Compatible infusion fluids Sodium chloride 0.9% or glucose 5%
Adverse
effects Arrhythmias, hypotension, tachycardia & convulsions. Signs of toxicity: nausea, palpitations,
twitching and convulsions (see BNF for full list of adverse effects)
Monitoring Heart rate and blood pressure monitoring should be recorded every hour for the first four hours
and then every two hours if stable
Management
and dose
reduction
Aminophylline infusions should be continued for at least 24 hours with review by medical staff at
agreed intervals, and may be continued for a further 24-48 hours. Tachyarrhythmias tend to be
the main reason for early discontinuation and therefore monitoring of potassium is essential. The
aim is to reduce the infusion over a 10-12 hour period of time once stable.
It is recommended that dose reduction begin in the morning, aiming to stop the infusion by mid to
late afternoon. This allows oral theophyllines (if appropriate) to be given that evening. The infusion
rate should be reduced every 2 hours with a medical review late in the afternoon prior to stopping
pf2

Partial preview of the text

Download Aminophylline for COPD Exacerbations: Dosage, Monitoring, Side Effects and more Schemes and Mind Maps History in PDF only on Docsity!

Intravenous Aminophylline (Adults)

Theophylline is a bronchial smooth muscle relaxant and bronchodilator. Intravenous (IV) theophylline is only available as aminophylline, which is a pro-drug of theophylline. Indication Intravenous Aminophylline may be used for ACUTE exacerbation of Chronic Obstructive Lung Disease (COPD) - to be used as an adjunct to the management of exacerbations of COPD if there is an inadequate response to nebulised bronchodilators.

Before using intravenous aminophylline for an exacerbation of COPD please consider whether patient may be a suitable for Non Invasive Ventilation. (For example patients with hypercapnic respiratory failure and a pH <7.35)

Please discuss use of intravenous aminophylline with a SpR or Consultant as potential side effects may outweigh benefits and evidence of benefit in COPD is weak. Significant side effects include arrhythmias and we would recommend avoiding its use in patients with any significant arrhythmia such as Atrial Fibrillation.

The loading dose is given only if life threatening features are present and if the patient is NOT already taking oral theophyllines.

IV Aminophylline should be the first line IV therapy in patients with COPD, whereas IV aminophylline or IV salbutamol can be used for patients with asthma if they are not responding to standard treatment. We would recommend all patients with acute asthma who are ill enough to need aminophylline IV are discussed with a SpR or consultant Check the drug history

If the patient usually takes maintenance aminophylline or theophylline therapy, check the theophylline serum level on admission and omit the loading dose.

For obese patients use IBW for dosing

IBW = Ideal body weight IBW (kg) for men = [(height (cm) – 154) x 0.9 ] + 50 IBW (kg) for women = [(height (cm) – 154) x 0.9 ] + 45.

Loading dose

5mg / kg aminophylline IV (max 500mg)- Write “LOADING DOSE” on the prescription

Add dose to 100mL of a compatible infusion fluid Administer using a rate controlled infusion pump over 20 minutes Monitoring during the bolus dose

If a patient experiences acute adverse effects i.e. palpitations, tachycardia, hypotension, whilst the loading dose is being infused, the infusion may be stopped for 5-10 minutes or administered at a slower rate. Ideally the patient should be cardiac monitored during the loading dose for these reasons Maintenance dose

500 micrograms / kg / hour ( Elderly: 300 micrograms / kg / hour)

Add 500mg to 500mL or 250mg to 250mL of a compatible infusion fluid (1mg/mL). Administer using a rate controlled infusion pump. Prescribe as mg / hour NOT mL / hour Maximum concentration

25mg in 1ml Maximum rate of administration

25mg per minute

Compatible infusion fluids Sodium chloride 0.9% or glucose 5%

Adverse effects

Arrhythmias, hypotension, tachycardia & convulsions. Signs of toxicity: nausea, palpitations, twitching and convulsions (see BNF for full list of adverse effects)

Monitoring (^) Heart rate and blood pressure monitoring should be recorded every hour for the first four hours and then every two hours if stable

Management and dose reduction

Aminophylline infusions should be continued for at least 24 hours with review by medical staff at agreed intervals, and may be continued for a further 24-48 hours. Tachyarrhythmias tend to be the main reason for early discontinuation and therefore monitoring of potassium is essential. The aim is to reduce the infusion over a 10-12 hour period of time once stable.

It is recommended that dose reduction begin in the morning, aiming to stop the infusion by mid to late afternoon. This allows oral theophyllines (if appropriate) to be given that evening. The infusion rate should be reduced every 2 hours with a medical review late in the afternoon prior to stopping

completely, and to confirm that oral theophyllines are to be started. If indicated the oral theophyllines should be given at the evening drug round.

Once a decision has been made to wean off the Aminophylline the rate should be halved every 2 hours. The best time to start the weaning process is in the morning when any adverse effects can be picked up whilst medical staff are available for review. Therapeutic drug monitoring

Therapeutic range = 10 to 20 mg/L  (^) In patients receiving oral theophyllines prior to admission to hospital, plasma levels should be done before the aminophylline infusion is started. 2  (^) Aminophylline levels should be measured 4-6 hours after the start of the intravenous infusion and checked on a daily basis thereafter. 2  (^) When starting oral theophyllines after the infusion- restart at the dose as prior to admission (if admission dose showed therapeutic levels- adjust the dose accordingly if not) or if newly started at a dose of 225mg BD oral aminophylline (Hospital Formulary choice)  (^) When starting oral theophyllines after the infusion, the plasma levels should be checked no sooner than 2 days after the infusion has finished. This confirms that the oral dose is correct for the patient and not in the toxic range. This can be done whilst an inpatient or followed up by the GP. Major factors influencing serum levels

Liver impairment, congestive heart failure, severe pulmonary obstruction, smoker. Interacting medicines e.g. antibacterials (azithromycin, ciprofloxacin, clarithromycin, erythromycin, isoniazid, rifampicin), antifungals (fluconazole, ketoconazole), fluvoxamine, carbamazepine, cimetidine, phenytoin, St John’s wort. This is not an exhaustive list. Refer to the BNF or Ward Pharmacist. Examples of calculations

Patient 1 : Weight = 70kg Patient 45 years old

Loading dose:

5mg/kg = 5mg x 70kg = 350mg- add to 100ml of infusion fluid and administer over 20 minutes

Maintenance Dose:

500micrograms/kg/hour = 500micrograms x 70kg per hour = 35000micrograms/hr = 35mg per hour

Add 500mg aminophylline to 500ml infusion fluid= 1mg/ml concentration

Set rate controlled infusion pump at 35ml per hour

Weaning process: halve the infusion rate every 2 hours- 35ml per hour to 18ml per hour to 9ml per hour to 4ml per hour to 2ml per hour for 2 hours then stop

Patient 2 : Weight = 55kg Patient 87years old

Loading dose:

5mg/kg = 5mg x 55kg = 275mg- add to 100ml infusion fluid and administer over 20 minutes

Maintenance dose:

300micrograms/kg/hour = 300micrograms x 55kg per hour = 16500 micrograms= 16.5mg (17mg) per hour

Add 250mg aminophylline to 250ml infusion fluid= 1mg/ml concentration

Set rate controlled infusion pump at 17ml per hour

Weaning process: halve the infusion rate every 2 hours- 17ml per hour to 8ml per hour to 4ml per hour to 2ml per hour for 2 hours then stop

References 1

2 British Guideline on the Management of Asthma. BTS and SIGN, Revised June 2009, Accessed from http://www.sign.ac.uk National Institute for Health and Clinical Excellence (NICE). Chronic obstructive pulmonary disease. Clinical Guideline No 12, 2004. Accessed from www.nice.org.uk

Ellen Sinden, PGH Pharmacy and Dr Simon Crowther, Thoracic Consultant PGH. Contributions by Laura Dollery, RBH Pharmacy, Dr David Morgan and Dr Timothy Shaw, Thoracic Consultants RBH July 2013. Adapted with permission from guidelines by Dorset County Hospital NHS Trust (Author Christine Dodd, Clinical Pharmacy Manager) and Poole Hospital. Review Date: September 2016